Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2024-03-13 Director's Dealing
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2024-03-13 English
FORM 4
Director's Dealing
2024-03-13 English
FORM 4
Director's Dealing
2024-03-13 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2024-03-04 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled as a "PRELIMINARY PROXY STATEMENT" and references Schedule 14A, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is clearly a proxy solicitation document for a Special Meeting of Stockholders to be held on April 4, 2024. The content includes detailed information about the meeting, voting procedures, proposals to be voted on (including a reverse stock split and adjournment proposal), and instructions for shareholders on how to vote. There is no indication that this is a report of voting results or a voting rights announcement, nor is it an annual report, earnings release, or any other financial report. The document is not a notice of dividend, nor a management or governance report. It is a proxy solicitation document intended to provide shareholders with information to make informed voting decisions at the meeting. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and detailed content confirm it is the proxy statement itself, not just an announcement or notice.
2024-02-23 English
SC 13G/A
Major Shareholding Notification
2024-02-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.